RxDoctor Payments Data

Hany Rezk, MD

Internal Medicine · New Castle, PANPI 1386732147

Payments from drug & device makers

$3,134in general payments, 2019–2025

Across 177 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$502
  • Boehringer Ingelheim$493
  • AstraZeneca$383
  • Amarin Pharma, Inc.$315
  • Lilly USA, LLC$237
  • E.r. Squibb & Sons, L.L.C.$230
  • plus $974 from 17 others

What the payments were for

  • Food & beverage$3,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,134 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,227
Medicare patients
132
Services billed
891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin105$107,373
EliquisApixaban146$91,847
XareltoRivaroxaban71$51,909
TradjentaLinagliptin33$37,192
OzempicSemaglutide34$34,957
JanuviaSitagliptin Phosphate47$32,187
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$24,557
FarxigaDapagliflozin Propanediol37$23,153
VascepaIcosapent Ethyl33$17,432
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$10,700
SynjardyEmpagliflozin/Metformin Hcl12$7,598
Icosapent Ethyl21$7,360
Humalog Kwikpen U-100Insulin Lispro32$7,332
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$6,514
Atorvastatin Calcium517$5,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$493$152,163150 claims
PfizerEliquis, Paxlovid$81$93,276157 claims
Johnson & JohnsonXarelto$502$51,90971 claims
Novo NordiskOzempic$138$34,95734 claims
MerckJanuvia$163$32,18747 claims
GSKTrelegy Ellipta$61$24,55717 claims
AstraZenecaFarxiga$383$23,15337 claims
AbbVieSynthroid$87$1,44020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in New Castle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →